Developer docs
API playgroundTry for free, no card

Search company profiles

Interpace Biosciences

Full company profile

uuid0004ywh

Namestring
Interpace Biosciences
Legal namestring
Interpace Biosciences, Inc.
Websiteurl
interpace.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Interpace Biosciences, Inc. (OTCQX: IDXG) is a publicly traded molecular diagnostics company headquartered in Parsippany, New Jersey, that commercializes proprietary laboratory tests used by specialty physicians and medical centers to evaluate indeterminate thyroid nodules. The company operates through its core subsidiary Interpace Diagnostics, which runs a CLIA-certified clinical laboratory that performs two commercialized assays in combination: ThyGeNEXT, a next-generation sequencing-based mutation profiling test that identifies genetic mutations highly indicative of thyroid cancer when traditional cytology is inconclusive, and ThyraMIRv2, a proprietary microRNA expression classifier that helps physicians identify thyroid nodules least likely to be malignant. The franchise addresses a defined clinical decision point — the indeterminate thyroid nodule — where the tests provide evidence-based risk stratification intended to reduce unnecessary surgeries and avoid missed cancers.

The business model is a usage-based clinical laboratory services model: healthcare providers order tests through the company's physician portal, specimens are processed at the company's CLIA-certified laboratory, and Interpace is reimbursed by Medicare, private insurance, and direct billing for each test performed. Following the May 2025 discontinuation of the PancraGEN pancreatic cyst test (specimens no longer accepted after May 2, 2025), the company derives 100% of revenue from its thyroid testing franchise. The go-to-motion is enterprise-style direct engagement with endocrinologists, endocrine surgeons, and hospital systems in the U.S. and internationally, supported by a physician portal, sales coverage, and an investor-facing communications program.

Operationally, the company has executed a multi-year strategic repositioning: it sold the Interpace Pharma Solutions biopharma services business to Flagship Biosciences in August 2022, exited pancreatic testing in 2025, fully paid off all outstanding debt in Q4 2025, and converted all preferred stock to common stock in January 2026 — at which point Ampersand Capital Partners held approximately 50% and 1315 Capital Partners approximately 34% of the approximately 27.7 million pro forma basic shares outstanding. With growing thyroid volume, expanding gross margins (65% in Q1 2026, up from 59% pro forma), and a debt-free balance sheet, management has signaled intent to uplist to Nasdaq in 2026.

Short descriptiontext

Interpace Biosciences is a public molecular diagnostics company that operates a CLIA-certified clinical laboratory providing the ThyGeNEXT and ThyraMIRv2 tests to endocrinologists, endocrine surgeons, and medical centers for risk stratification of indeterminate thyroid nodules, reimbursed by Medicare and private insurers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostic tests, thyroid cancer diagnostics, next generation sequencing, microRNA expression testing, clinical laboratory services
Industry3 codes
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Thyroid Diagnostic Testing Services
TypeUsage Based
Description

Interpace Biosciences generates revenue through clinical laboratory testing services, specifically its ThyGeNEXT and ThyraMIRv2 molecular diagnostic tests for thyroid cancer. Revenue comes from Medicare, insurance reimbursements, and direct billing for molecular diagnostic testing services provided to healthcare providers evaluating patients with indeterminate thyroid nodules. The company discontinued its PancraGEN product line in May 2025 and now generates 100% of revenue from thyroid testing.

ir.interpace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Interpace Diagnostics
Description

Subsidiary that develops and commercializes molecular diagnostic tests including ThyGeNEXT and ThyraMIRv2 for thyroid cancer diagnosis

ir.interpace.com
Core offering1 text field

Interpace Biosciences, through its subsidiary Interpace Diagnostics, provides evidence-based molecular diagnostic testing services that risk-stratify cytologically indeterminate thyroid nodules. Its two commercialized tests, ThyGeNEXT (NGS-based mutation profiling) and ThyraMIR v2 (a proprietary microRNA classifier), are used together to help physicians determine whether nodules are likely malignant, reducing unnecessary surgeries and missed cancers. Following the May 2025 discontinuation of PancraGEN, 100% of revenue is generated by the thyroid testing franchise.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Gross margin expanded to 65% in Q1 2026 from 59% year-over-year on pro forma basis
+4 more records
Product overview1 text field

Interpace Biosciences provides molecular diagnostic tests for early cancer diagnosis through its subsidiary Interpace Diagnostics. The company offers two commercialized molecular tests: ThyGeNEXT (a Next Generation Sequencing-based mutation profile that identifies cancer-indicative mutations from thyroid nodules when cytology is indeterminate) and ThyraMIR v2 (a proprietary microRNA-based classifier used in combination with ThyGeNEXT). Following the May 2025 discontinuation of PancraGEN, the company now focuses exclusively on thyroid diagnostics, providing specialized testing services to specialty physicians and medical centers throughout the U.S. and internationally.

Product and service2 records
1ThyGeNEXT
CategoryMolecular diagnostic test
Description

A Next Generation Sequencing (NGS)-based mutation profile performed by Interpace's CLIA-certified laboratory that identifies genetic mutations from thyroid nodules highly indicative of thyroid cancer when traditional cytology results are indeterminate. Used in combination with ThyraMIR v2 and ordered by specialty physicians and medical centers through the Interpace physician portal.

2ThyraMIR v2
CategoryMolecular diagnostic test
Description

A proprietary microRNA-based gene-expression classifier used together with ThyGeNEXT to assist physicians in identifying thyroid nodules least likely to be malignant when cytology is indeterminate. Performed as part of Interpace's combined NGS plus microRNA testing workflow for specialty physicians and medical centers.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthersAnnounced on2022-08-01
Description

Interpace sold its Interpace Pharma Solutions division to Flagship Biosciences in August 2022, divesting its biopharma services business to focus exclusively on thyroid diagnostics.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Veracyte's Afirma Genomic Sequencing Classifier is the leading molecular test for evaluating indeterminate thyroid nodules, directly competing with Interpace's ThyGeNEXT and ThyraMIRv2 in the same indication and customer base of endocrinologists and endocrine surgeons.

TypeBroad incumbent
Description

NeoGenomics is a specialty oncology-focused clinical laboratory offering molecular and genetic testing services, including in thyroid and other solid tumors. It is a broader incumbent with substantially greater scale than Interpace.

TypeDirect peer
Description

Castle Biosciences commercializes molecular diagnostic tests that guide treatment decisions in cancers including thyroid (ThyroSeq-v2 alternative profiles), using a similar specialty-physician GTM motion and proprietary genomic/molecular classifier approach.

TypeBroad incumbent
Description

Myriad Genetics is an established molecular diagnostics company with a portfolio of gene-based tests across oncology, including hereditary cancer risk assessment. It competes with Interpace in the broader specialty-physician oncology testing channel.

TypeEmerging player
Description

Natera is a molecular diagnostics company specializing in cell-free DNA and genetic testing across oncology, women's health, and organ health. While not focused on thyroid nodules, it competes in the molecular diagnostics space serving specialty physicians.

TypeBroad incumbent
Description

Quest Diagnostics is one of the largest clinical laboratory companies in the U.S., offering a broad menu of molecular and genetic tests, including endocrine and oncology panels, and has the scale and payer relationships to compete with Interpace's thyroid franchise.

TypeBroad incumbent
Description

LabCorp is a leading global clinical laboratory network that offers a comprehensive menu of molecular diagnostic and esoteric tests, including in oncology and endocrinology, and competes with Interpace via broad physician relationships and integrated lab services.

TypeEmerging player
Description

BioReference, an Opko Health subsidiary, is a full-service clinical laboratory offering specialty molecular diagnostics including oncology panels, serving physicians and health systems with an esoteric testing menu that overlaps with Interpace's specialty oncology channel.

TypeBroad incumbent
Description

Exact Sciences is a leading molecular diagnostics company best known for Cologuard, with an expanding oncology portfolio that includes liquid biopsy and treatment-selection tests. It is a broader incumbent in molecular cancer diagnostics with significantly greater scale.

TypeEmerging player
Description

Guardant Health is a leading precision oncology company specializing in liquid biopsy tests for cancer detection and monitoring. While primarily focused on blood-based oncology testing, it competes with Interpace in the molecular diagnostics market serving oncologists and specialists.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Interpace Biosciences

Molecular Diagnosticsinterpace.com

Interpace Biosciences is a public molecular diagnostics company that operates a CLIA-certified clinical laboratory providing the ThyGeNEXT and ThyraMIRv2 tests to endocrinologists, endocrine surgeons, and medical centers for risk stratification of indeterminate thyroid nodules, reimbursed by Medicare and private insurers.

What Interpace Biosciences does

Interpace Biosciences, Inc. (OTCQX: IDXG) is a publicly traded molecular diagnostics company headquartered in Parsippany, New Jersey, that commercializes proprietary laboratory tests used by specialty physicians and medical centers to evaluate indeterminate thyroid nodules. The company operates through its core subsidiary Interpace Diagnostics, which runs a CLIA-certified clinical laboratory that performs two commercialized assays in combination: ThyGeNEXT, a next-generation sequencing-based mutation profiling test that identifies genetic mutations highly indicative of thyroid cancer when traditional cytology is inconclusive, and ThyraMIRv2, a proprietary microRNA expression classifier that helps physicians identify thyroid nodules least likely to be malignant. The franchise addresses a defined clinical decision point — the indeterminate thyroid nodule — where the tests provide evidence-based risk stratification intended to reduce unnecessary surgeries and avoid missed cancers.

The business model is a usage-based clinical laboratory services model: healthcare providers order tests through the company's physician portal, specimens are processed at the company's CLIA-certified laboratory, and Interpace is reimbursed by Medicare, private insurance, and direct billing for each test performed. Following the May 2025 discontinuation of the PancraGEN pancreatic cyst test (specimens no longer accepted after May 2, 2025), the company derives 100% of revenue from its thyroid testing franchise. The go-to-motion is enterprise-style direct engagement with endocrinologists, endocrine surgeons, and hospital systems in the U.S. and internationally, supported by a physician portal, sales coverage, and an investor-facing communications program.

Operationally, the company has executed a multi-year strategic repositioning: it sold the Interpace Pharma Solutions biopharma services business to Flagship Biosciences in August 2022, exited pancreatic testing in 2025, fully paid off all outstanding debt in Q4 2025, and converted all preferred stock to common stock in January 2026 — at which point Ampersand Capital Partners held approximately 50% and 1315 Capital Partners approximately 34% of the approximately 27.7 million pro forma basic shares outstanding. With growing thyroid volume, expanding gross margins (65% in Q1 2026, up from 59% pro forma), and a debt-free balance sheet, management has signaled intent to uplist to Nasdaq in 2026.

Interpace Biosciences firmographics

Firmographics
Name
Interpace Biosciences
Legal name
Interpace Biosciences, Inc.
Website
https://interpace.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Interpace Biosciences is a public molecular diagnostics company that operates a CLIA-certified clinical laboratory providing the ThyGeNEXT and ThyraMIRv2 tests to endocrinologists, endocrine surgeons, and medical centers for risk stratification of indeterminate thyroid nodules, reimbursed by Medicare and private insurers.
Ownership category
akta.pro rank

Interpace Biosciences industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Molecular diagnostic tests
  • Thyroid cancer diagnostics
  • Next generation sequencing
  • MicroRNA expression testing
  • Clinical laboratory services

Where Interpace Biosciences is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Interpace Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Thyroid Diagnostic Testing Services: Interpace Biosciences generates revenue through clinical laboratory testing services, specifically its ThyGeNEXT and ThyraMIRv2 molecular diagnostic tests for thyroid cancer. Revenue comes from Medicare, insurance reimbursements, and direct billing for molecular diagnostic testing services provided to healthcare providers evaluating patients with indeterminate thyroid nodules. The company discontinued its PancraGEN product line in May 2025 and now generates 100% of revenue from thyroid testing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Interpace Biosciences product offering

Product offering

Core offering

Interpace Biosciences, through its subsidiary Interpace Diagnostics, provides evidence-based molecular diagnostic testing services that risk-stratify cytologically indeterminate thyroid nodules. Its two commercialized tests, ThyGeNEXT (NGS-based mutation profiling) and ThyraMIR v2 (a proprietary microRNA classifier), are used together to help physicians determine whether nodules are likely malignant, reducing unnecessary surgeries and missed cancers. Following the May 2025 discontinuation of PancraGEN, 100% of revenue is generated by the thyroid testing franchise.

Product overview

Interpace Biosciences provides molecular diagnostic tests for early cancer diagnosis through its subsidiary Interpace Diagnostics. The company offers two commercialized molecular tests: ThyGeNEXT (a Next Generation Sequencing-based mutation profile that identifies cancer-indicative mutations from thyroid nodules when cytology is indeterminate) and ThyraMIR v2 (a proprietary microRNA-based classifier used in combination with ThyGeNEXT). Following the May 2025 discontinuation of PancraGEN, the company now focuses exclusively on thyroid diagnostics, providing specialized testing services to specialty physicians and medical centers throughout the U.S. and internationally.

Differentiator

Problem solved

Functional benefit

Brands

  • Interpace Diagnostics: Subsidiary that develops and commercializes molecular diagnostic tests including ThyGeNEXT and ThyraMIRv2 for thyroid cancer diagnosis

Products and services

  • ThyGeNEXT A Next Generation Sequencing (NGS)-based mutation profile performed by Interpace's CLIA-certified laboratory that identifies genetic mutations from thyroid nodules highly indicative of thyroid cancer when traditional cytology results are indeterminate. Used in combination with ThyraMIR v2 and ordered by specialty physicians and medical centers through the Interpace physician portal.
  • ThyraMIR v2 A proprietary microRNA-based gene-expression classifier used together with ThyGeNEXT to assist physicians in identifying thyroid nodules least likely to be malignant when cytology is indeterminate. Performed as part of Interpace's combined NGS plus microRNA testing workflow for specialty physicians and medical centers.

Quantifiable outcome

  • Gross margin expanded to 65% in Q1 2026 from 59% year-over-year on pro forma basis
  • +4 more outcomes

Companies that use Interpace Biosciences

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Interpace Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature2 records

Interpace Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Flagship BiosciencesminorOthers · 1 August 2022Interpace sold its Interpace Pharma Solutions division to Flagship Biosciences in August 2022, divesting its biopharma services business to focus exclusively on thyroid diagnostics.

Scale indicators9 records

Recent moves7 records

Expansion highlights4 records

Interpace Biosciences competitors and assessment

Company assessment

Direct peers

  • Veracyte: Veracyte's Afirma Genomic Sequencing Classifier is the leading molecular test for evaluating indeterminate thyroid nodules, directly competing with Interpace's ThyGeNEXT and ThyraMIRv2 in the same indication and customer base of endocrinologists and endocrine surgeons.
  • Castle Biosciences: Castle Biosciences commercializes molecular diagnostic tests that guide treatment decisions in cancers including thyroid (ThyroSeq-v2 alternative profiles), using a similar specialty-physician GTM motion and proprietary genomic/molecular classifier approach.

Broad incumbents

  • NeoGenomics: NeoGenomics is a specialty oncology-focused clinical laboratory offering molecular and genetic testing services, including in thyroid and other solid tumors. It is a broader incumbent with substantially greater scale than Interpace.
  • Myriad Genetics: Myriad Genetics is an established molecular diagnostics company with a portfolio of gene-based tests across oncology, including hereditary cancer risk assessment. It competes with Interpace in the broader specialty-physician oncology testing channel.
  • Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory companies in the U.S., offering a broad menu of molecular and genetic tests, including endocrine and oncology panels, and has the scale and payer relationships to compete with Interpace's thyroid franchise.
  • Laboratory Corporation of America (LabCorp): LabCorp is a leading global clinical laboratory network that offers a comprehensive menu of molecular diagnostic and esoteric tests, including in oncology and endocrinology, and competes with Interpace via broad physician relationships and integrated lab services.
  • Exact Sciences: Exact Sciences is a leading molecular diagnostics company best known for Cologuard, with an expanding oncology portfolio that includes liquid biopsy and treatment-selection tests. It is a broader incumbent in molecular cancer diagnostics with significantly greater scale.

Emerging players

  • Natera: Natera is a molecular diagnostics company specializing in cell-free DNA and genetic testing across oncology, women's health, and organ health. While not focused on thyroid nodules, it competes in the molecular diagnostics space serving specialty physicians.
  • BioReference Laboratories (Opko Health): BioReference, an Opko Health subsidiary, is a full-service clinical laboratory offering specialty molecular diagnostics including oncology panels, serving physicians and health systems with an esoteric testing menu that overlaps with Interpace's specialty oncology channel.
  • Guardant Health: Guardant Health is a leading precision oncology company specializing in liquid biopsy tests for cancer detection and monitoring. While primarily focused on blood-based oncology testing, it competes with Interpace in the molecular diagnostics market serving oncologists and specialists.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Interpace Biosciences social profiles

Digital presence

Interpace Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Interpace Biosciences leadership team

Management profile

Number of profiles

Profiles4 records

Interpace Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Interpace Biosciences funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Interpace Biosciences M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Interpace Biosciences

What does Interpace Biosciences do?

Interpace Biosciences, through its subsidiary Interpace Diagnostics, provides evidence-based molecular diagnostic testing services that risk-stratify cytologically indeterminate thyroid nodules. Its two commercialized tests, ThyGeNEXT (NGS-based mutation profiling) and ThyraMIR v2 (a proprietary microRNA classifier), are used together to help physicians determine whether nodules are likely malignant, reducing unnecessary surgeries and missed cancers. Following the May 2025 discontinuation of PancraGEN, 100% of revenue is generated by the thyroid testing franchise.

Is Interpace Biosciences a public or private company?

Interpace Biosciences is a public company. It is classified as public and is currently operating.

When was Interpace Biosciences founded?

Interpace Biosciences was founded in 2014. It employs 101 to 250 people.

Where is Interpace Biosciences based?

Interpace Biosciences is headquartered in Parsippany, United States, in the North America region.

How does Interpace Biosciences make money?

One revenue line is on record: thyroid Diagnostic Testing Services.

Who are Interpace Biosciences's main competitors?

Direct peers on record are Veracyte and Castle Biosciences. Broad incumbents are NeoGenomics, Myriad Genetics, Quest Diagnostics, Laboratory Corporation of America (LabCorp) and Exact Sciences. Emerging players are Natera, BioReference Laboratories (Opko Health) and Guardant Health.

Does Interpace Biosciences have an API?

No public API is recorded for Interpace Biosciences.

What industry is Interpace Biosciences in?

Interpace Biosciences's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerInterpace Biosciences, Inc. Provides Preliminary, Unaudited Earnings Guidance for the Third Quarter Ended September 30, 2026Interpace Biosciences provided preliminary, unaudited earnings guidance for Q3 2026, expecting revenue of $10.1-10.4 million. This represents an increase of approximately 11% to 14% compared with $9.1 million in Q2 2026 and 15% to 18% compared with $8.8 million in Q3 2025.TradingViewInterpace Biosciences, Inc. (IDXG) Sees Q3 Revenue $10.1M–$10.4M, Up 11%–14% QoQInterpace Biosciences expects preliminary Q3 2026 revenue of $10.1M–$10.4M, up 11%–14% from Q2's $9.1M and 15%–18% from Q3 2025's $8.8M. The figures are unaudited and subject to review, with no profitability or margin guidance provided.BioSpaceInterpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq UplistingInterpace Biosciences announced a 1-for-5 reverse stock split effective August 27, 2026, reducing outstanding shares from about 27.7 million to 5.5 million. The split aims to meet Nasdaq's minimum bid price requirement for uplisting. The company's board approved the split on August 20, 2026.Defense WorldCritical Contrast: Interpace Biosciences (OTCMKTS:IDXG) versus Ethema Health (OTCMKTS:GRST)Interpace Biosciences outperformed Ethema Health across six of eight financial metrics, including higher revenue, net income, and profitability ratios. The comparison highlights significant differences in operational efficiency, with Interpace posting a 65.25% net margin against Ethema's loss, while Ethema reported $18.76 million in revenue compared to Interpace's $38.73 million.BioSpaceInterpace Biosciences Announces Second Quarter 2026 Financial and Business ResultsInterpace Biosciences reported Q2 2026 revenue of $9.1 million, down 1% year-over-year, with thyroid revenue up 9%. The company posted $0.3 million income from continuing operations and $0.7 million adjusted EBITDA. It plans to add a Chief Scientific Officer in September and is developing a pancreatic cancer program.Ticker ReportInterpace Biosciences (OTCMKTS:IDXG) Issues Quarterly Earnings ResultsInterpace Biosciences announced its quarterly earnings results on Monday, reporting $0.01 earnings per share for the quarter according to Zacks. The company posted a return on equity of 219.07% and a net margin of 65.25%, while its stock rose 5.6% to $1.70 on above-average trading volume. The molecular diagnostics provider operates in the United States, offering tests including PancraGEN, ThyGeNEXT, ThyraMIR, and RespriDx for evaluating cancer risk.Stock TitanInterpace Biosciences Q2 Earnings: $9.1M RevenueInterpace Biosciences reported Q2 2026 revenue of $9.1 million and income from continuing operations of $0.3 million, a reversal from a loss of $0.5 million in the prior year quarter, driven by 9% year-over-year thyroid revenue growth on a Pro Forma basis. Gross margin expanded to 62% from 54% Pro Forma, Adjusted EBITDA improved to $0.7 million from $0.2 million, and the company maintains a debt-free balance sheet with $2.7 million in cash as of June 30, 2026. The company also provided an update on its pancreatic cancer program, which is in analytical validation with no revenue expected in 2026.GlobeNewswireInterpace Biosciences Announces First Quarter 2026 Financial and Business ResultsInterpace Biosciences reported Q1 2026 revenue of $9.0 million with $0.8 million income from continuing operations, reflecting a 12% year-over-year increase in thyroid revenue and 10% growth in thyroid volume. The company's gross margin expanded to 65% from 59% on a pro forma basis, while Adjusted EBITDA improved to $1.6 million from $0.8 million in the prior year pro forma quarter. Interpace reaffirmed its 2026 guidance of approximately 16% year-over-year thyroid revenue growth and highlighted its debt-free balance sheet and operational efficiency gains from laboratory automation and AI-enabled productivity initiatives.